GSK: drug shows meaningful response rate in multiple myeloma
(CercleFinance.com) - An experimental GlaxoSmithKline drug has obtained a clinically meaningful response rate in patients with relapsed/refractory multiple myeloma, the drugmaker said on Tuesday.
Thirty out of the 97 patients (31%) in the pivotal study achieved an overall response, GSK said. Out of these responders, 18 patients achieved a very good partial response or better, including three patients with complete responses, it said.
GSK also confirmed the submission of an application to the US Food and Drug Administration (FDA) seeking approval of belantamab mafodotin for patients with this heavily pre-treated multiple myeloma.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Thirty out of the 97 patients (31%) in the pivotal study achieved an overall response, GSK said. Out of these responders, 18 patients achieved a very good partial response or better, including three patients with complete responses, it said.
GSK also confirmed the submission of an application to the US Food and Drug Administration (FDA) seeking approval of belantamab mafodotin for patients with this heavily pre-treated multiple myeloma.
Copyright (c) 2019 CercleFinance.com. All rights reserved.